Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis
This study has been completed.
Sponsor:
Novartis
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00459537
First received: April 10, 2007
Last updated: May 3, 2011
Last verified: May 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study will evaluate the efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride applied daily versus 5% amorolfine nail lacquer applied twice a week in patients with mild to moderate toenail onychomycosis, for a total treatment duration of 48 weeks.
| Condition | Intervention | Phase |
|---|---|---|
|
Onychomycosis |
Drug: terbinafine hydrogen chloride Drug: amorolfine nail lacquer |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis |
Resource links provided by NLM:
Further study details as provided by Novartis:
Primary Outcome Measures:
- Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks [ Time Frame: Week 52 ] [ Designated as safety issue: No ]Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.
- Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks. [ Time Frame: Week 52 ] [ Designated as safety issue: No ]Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.
Secondary Outcome Measures:
- Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Patients for 48 Weeks. [ Time Frame: Week 52 ] [ Designated as safety issue: No ]Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and <= 10% residual involvement of the target toenail.
- Percentage of Participants With Mycological Cure at End of Study After Treating Patients for 48 Weeks [ Time Frame: Week 52 ] [ Designated as safety issue: No ]Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes
- Safety and Tolerability Assessed by the Number of Participants With Adverse Events [ Time Frame: Week 52 ] [ Designated as safety issue: Yes ]Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE or SAE and death. Additional details can be found in the Adverse Event Section.
| Enrollment: | 1029 |
| Study Start Date: | March 2007 |
| Study Completion Date: | January 2009 |
| Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Terbinafine
10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.
|
Drug: terbinafine hydrogen chloride
10 % terbinafine hydrogen chloride (HCL)
Other Name: Lamisil
|
|
Active Comparator: Amorolfine
5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.
|
Drug: amorolfine nail lacquer
5 % amorolfine nail lacquer
|
Eligibility| Ages Eligible for Study: | 12 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male and females 12 - 75 years of age
- Fungal toenail infection of one or both of the large (great) toenails
- The nail infection must be due to a dermatophyte, (mixed infections [dermatophyte and non-dermatophyte] are not allowed)
- The target toenail area must have at least 25% to no more than 75% disease involvement without spikes.
Exclusion Criteria:
- Target foot must not have severe plantar (moccasin) tinea pedis that would require systemic therapy. Mild to moderate tinea pedis (athlete's foot) infection should be treated with terbinafine prior to baseline or at any time during the trial. Other topical treatments for athlete's foot may be recommended at the discretion of the investigator.
- Subjects must not have abnormalities of the nail that could prevent a normal appearing nail if clearing of infection is achieved
- No administration of systemic antifungal medications within 6 months prior to screening visit
- No application of prescription topical antifungal medications for toenail fungus within 3 months or other commercially available topical medications for toenail fungus applied directly to the toenails within 1 month prior to screening visit
- Patients with the target toenail involving the matrix (lunula) or having less than 2mm clear (unaffected) nail plate length beyond the proximal fold.
- Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail.
- No professional pedicures or application of any nail polish product or nail cosmetic to the toenails after the screening visit
- Known pregnancy or lactation at time of enrollment
Other protocol-defined inclusion/exclusion criteria may apply
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00459537
Locations
| Finland | |
| Novartis Investigative Site | |
| Various Cities, Finland | |
| France | |
| Novartis Investigative Site | |
| Various Cities, France | |
| Germany | |
| Novartis Investigative Site | |
| Various Cities, Germany | |
| Hungary | |
| Novartis Investigative Site | |
| Various Cities, Hungary | |
| Iceland | |
| Novartis Investigative Site | |
| Various Cities, Iceland | |
| Norway | |
| Novartis Investigative Site | |
| Various Cities, Norway | |
| Poland | |
| Novartis Investigative Site | |
| Various Cities, Poland | |
| Russian Federation | |
| Novartis Investigative Site | |
| Various Cities, Russian Federation | |
| Spain | |
| Novartis Investigative Site | |
| Various Cities, Spain | |
| Turkey | |
| Novartis Investigative Site | |
| Various Cities, Turkey | |
Sponsors and Collaborators
Novartis
Investigators
| Study Director: | Novartis | Novartis |
More Information
No publications provided
| Responsible Party: | External Affairs, Novartis |
| ClinicalTrials.gov Identifier: | NCT00459537 History of Changes |
| Other Study ID Numbers: | CSFO327N2303 |
| Study First Received: | April 10, 2007 |
| Results First Received: | January 19, 2011 |
| Last Updated: | May 3, 2011 |
| Health Authority: | Finland: Finnish Medicines Agency France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Germany: Federal Institute for Drugs and Medical Devices Hungary: Országos Gyógyszerészeti Intézet Iceland: Icelandic Medicines Control Agency Norway: Norwegian Medicines Agency Poland: Central Register of Clinical Trials Russia: Ministry of Health of the Russian Federation Spain: Ministry of Health Turkey: T.C. Sağlık Bakanlığı |
Keywords provided by Novartis:
|
Toenail fungus Onychomycosis Nail fungus Toenail fungal infection |
Tinea unguium Dermatophytes Foot dermatoses |
Additional relevant MeSH terms:
|
Onychomycosis Tinea Dermatomycoses Skin Diseases, Infectious Infection Mycoses Nail Diseases Skin Diseases |
Amorolfine Terbinafine Antifungal Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 23, 2013